

**Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice
from a European Panel**

P. Hadji^{1,*}, R.E. Coleman^{2,*}, C. Wilson², T. J. Powles³, P. Clézardin⁴, M. Aapro⁵, L. Costa⁶, J-J. Body⁷, C. Markopoulos⁸, D. Santini⁹, I. Diel¹⁰, A. Di Leo¹¹, D. Cameron¹², D. Dodwell¹³, I. Smith¹⁴, M. Gnant¹⁵, R. Gray¹⁶, N. Harbeck¹⁷, B. Thurlimann¹⁸, M. Untch¹⁹, J. Cortes²⁰, M. Martin²¹, U-S. Albert¹, P-F. Conte²², B. Ejlersen²³, J. Bergh²⁴, M. Kaufmann²⁵, I. Holen²

¹Dept. of Bone Oncology, Endocrinology and Reproductive Medicine, Philipps-University of Marburg, Frankfurt, Germany

²Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK

³Cancer Centre London, 49 Parkside, Wimbledon, London, UK

⁴INSERM, Research Unit UMR403, University of Lyon, School of Medicine Lyon-Est, Lyon, France

⁵Breast Center of the Multidisciplinary Oncology Institute, Genolier, Switzerland

⁶Hospital de Santa Maria & Lisbon School of Medicine, Institute of Molecular Biology, Lisbon, Portugal

⁷CHU Brugmann, University Libre de Bruxelles, Brussels, Belgium.

⁸Medical School, National University of Athens, Athens – Greece

⁹Medical Oncology, University Campus Bio-medico, Rome, Italy

¹⁰Institute for Gynaecological Oncology, Centre for Comprehensive Gynecology, Mannheim, Germany

¹¹Sandro Pitigliani Medical Oncology Unit, Dept. of Oncology, Hospital of Prato, Prato, Italy

¹²University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK

¹³Institute of Oncology, Bexley Wing, St James Hospital Leeds, UK

¹⁴The Royal Marsden Hospital and Institute of Cancer Research, London, UK

¹⁵Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Austria

¹⁶Clinical Trials and Epidemiological Unit, University of Oxford, Oxford, UK

¹⁷Breast Center, Dept. of Obstetrics and Gynaecology, University of Munich, Germany

¹⁸Kantonsspital St.Gallen, Breast Center, St.Gallen, Switzerland

¹⁹Gynecologic Oncology and Obstetrics, Schwanebecker, Chaussee, Berlin, Germany

²⁰Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

²¹Institute of Investigation Sanitaria Gregorio Marañón, University Complutense, Madrid, Spain

²²Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

²³Danish Breast Cancer Cooperative Group Statistical Center; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

²⁴Karolinska Institute and University Hospital, Stockholm, Sweden

²⁵Institute for Obstetrics and Gynaecology, Goethe University, Frankfurt, Germany

Address for correspondence: Prof RE Coleman, University of Sheffield, Weston Park Hospital, Whitham Road, Sheffield, S10 2SJ, UK. r.e.coleman@sheffield.ac.uk, +441142265000

*Joint first authors

Abstract

Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment induced bone loss and reduce the risk of disease recurrence and metastasis. Treatment benefits have been reported but bisphosphonates do not currently have regulatory approval for either of these potential indications. This consensus paper provides a review of the evidence and offers guidance to breast cancer clinicians on the use of bisphosphonates in early breast cancer.

Using the nominal group methodology for consensus a systematic review of the literature was augmented by a workshop held in October 2014 for breast cancer and bone specialists to

present and debate the available preclinical and clinical evidence for the use of adjuvant bisphosphonates. This was followed by a questionnaire to all members of the writing committee to identify areas of consensus.

The panel recommended that bisphosphonates should be considered as part of routine clinical practice for the prevention of cancer treatment induced bone loss in all patients with a T score of < -2.0 or ≥ 2 clinical risk factors for fracture. Compelling evidence from a meta-analysis of trial data of $>18,000$ patients supports clinically significant benefits of bisphosphonates on the development of bone metastases and breast cancer mortality in postmenopausal women or those receiving ovarian suppression therapy. Therefore the panel recommends that bisphosphonates (either intravenous zoledronic acid or oral clodronate) are considered as part of the adjuvant breast cancer treatment in this population and the potential benefits and risks discussed with relevant patients.

Key words; adjuvant, bisphosphonates, breast cancer, guidelines

Key Message: "A panel of European experts in breast cancer and bone health convened in a face to face meeting to discuss the available evidence and draft guidance on how bisphosphonates should be used, in addition to standard adjuvant therapy, in early breast cancer. Our manuscript provides a thorough review of the clinical randomised trial evidence evaluating the use of bisphosphonates to a) prevent cancer therapy induced bone loss and b) prevent metastases and improve cancer outcomes. We detail and summarise recommendations to aid clinicians on the use of adjuvant bisphosphonates in this context."

Introduction

Bisphosphonates have regulatory approval and are part of standard care for the prevention and treatment of osteoporosis and the prevention of skeletal related events associated with bone metastases from metastatic solid tumours and multiple myeloma¹. Bisphosphonates have also been studied in randomised trials in the adjuvant setting of early breast cancer to investigate their ability to prevent both cancer treatment induced bone loss and reduce disease recurrence and metastases. Bisphosphonates do not currently have regulatory approval for either of these indications. This consensus paper provides a review of the evidence and offers guidance on the use of bisphosphonates in both these additional settings.

Aims

To provide guidance for the use of bisphosphonates in patients with early breast cancer, focusing on cancer treatment induced bone loss (CTIBL) and the prevention of metastases.

Methods;

Consensus meeting; Using the nominal group methodology for consensus² individual leading experts from European stakeholders in the clinical management of breast cancer (medical/clinical oncologists, gynaecologists, surgeons), and experts in preclinical bone research were asked to present their opinions on the predefined aims of the consensus at a face to face meeting in October 2014. Following the presentations a structured discussion was undertaken to collate individual expert opinions and review relevant published literature (identified as per 'Data sources' below).

Consensus questionnaire; Following the consensus meeting a series of questions were developed to consolidate expert opinions. Voting on each question was anonymous and in the format of 'agreement' or 'disagreement' (graded strong or slightly) or neutral if a panel member felt there was insufficient evidence or he/she had insufficient knowledge to support a recommendation. Questionnaires were completed by 24/26 (90%) of experts and data was assessed. Detailed voting records for each question addressed to the panel are available online in the supplementary appendix (S1).

Data sources; A systematic literature search was conducted using Pubmed and MEDLINE databases from 1970 to 2014. In addition, the Cochrane Register of Controlled Trials and databases of ongoing and unpublished trials <http://www.clinicaltrials.gov> were searched. Conference proceedings from San Antonio Breast Cancer Symposium, European Society of Medical Oncology and American Society of Clinical Oncology (2000-2014) were reviewed. The key studies are summarised in figures 1 and 2. In addition, the panel had access to the EBCTCG meta-analysis findings before full publication.

Cancer treatment induced bone loss

The causes of bone loss in cancer patients and the functional consequences are multifactorial, occurring as a result of the anti-cancer therapies used to prevent tumour recurrence and pre-existing clinical risk factors for fracture (age, concurrent medications i.e. glucocorticoids, smoking status, low body mass index, family or personal history of fragility fracture, T score <- 2.5)^{1,3}. The speed of CTIBL depends on the menopausal status of the patients in addition to the cancer treatment received, and on average is more rapid than the natural rate of bone loss that occurs in postmenopausal women^{1,4}.

Premenopausal women

Premenopausal women have high circulating levels of ovarian secreted oestradiol and inhibins, which act directly on bone to maintain bone mass⁵. However, accelerated bone loss in premenopausal women will occur if ovarian failure is induced by anti-cancer treatment, or if the effects of oestrogen on bone are inhibited by selective oestrogen receptor modulators such as tamoxifen.

Effects of chemotherapy

Chemotherapy probably does not have a clinically significant direct toxic effect on bone in women who maintain menses⁶. Early bone loss has been observed during chemotherapy, but this is likely due to the induction of menopause, high doses of glucocorticoids used as antiemetics plus fatigue-related immobility, rather than the cytotoxic agents themselves⁷.

Effects of ovarian suppression

Loss or suppression of ovarian function from either chemotherapy or drugs affecting the hypothalamic-pituitary-gonadal (HPG) axis such as GnRH/LHRH analogues has been shown to cause rapid bone loss that persists for the duration of amenorrhoea⁸. In patients who receive chemotherapy and remain permanently amenorrhoeic, the indirect effects of chemotherapy on bone loss continue after cessation of chemotherapy⁹⁻¹¹.

In patients receiving GnRH analogues to suppress ovarian function (OFS), accelerated bone loss occurs during treatment but there is recovery after treatment is stopped, especially in those patients who resume menses^{12,13}. In the largest trial of OFS with endocrine therapy in

premenopausal women, bone mineral density (BMD) after 3 years was reduced by 11.3% and 7.3% at the lumbar spine and trochanter respectively. 75% of patients' regained menses after endocrine treatment stopped and BMD partially recovered (but did not reach baseline levels) at both skeletal sites over the next two years¹⁴. Moreover, bone loss in patients receiving anastrozole in addition to OFS was greater than that seen with tamoxifen plus OFS (-13.6% vs -9% at 3 years)¹⁴. The use of OFS and an aromatase inhibitor is likely to be increasing in routine clinical practice following a recent randomised trial showing significantly improved disease free survival in premenopausal women with high-risk disease treated with this endocrine strategy compared with the current standard, tamoxifen¹⁵.

Effects of tamoxifen

Tamoxifen is the most commonly used endocrine drug in premenopausal women with hormone receptor positive breast cancer, acting as an anti-oestrogen in breast cancer cells but with effects in bone that are dependent upon prevailing oestrogen levels. In premenopausal women, where the bone microenvironment is rich in oestradiol, tamoxifen taken for three years resulted in bone loss¹⁶. The effects of prolonged durations of tamoxifen should be studied further, since premenopausal women with breast cancer may now be recommended to continue with adjuvant tamoxifen for up to 10 years¹⁷.

Postmenopausal women

There is no clear evidence for a direct effect of chemotherapy on bone loss in postmenopausal women. In addition, tamoxifen reduces fracture incidence compared to placebo in a low bone oestrogen environment¹⁸ and thus does not contribute to endocrine therapy related bone loss

in this population. The major contributor to bone loss in a postmenopausal breast cancer population is the use of aromatase inhibitors (AI).

Bone effects of aromatase inhibitors

AIs improve disease outcomes in comparison to tamoxifen but are associated with increased fracture incidence¹. These agents prevent the conversion of androgens to oestrogen by the aromatase enzyme, thereby rapidly and dramatically reducing circulating serum oestradiol levels¹⁹. This decline in oestradiol is associated with a 40% relative increase in fracture rate compared to tamoxifen²⁰. When compared to placebo the excess fracture rate during AI therapy is less²¹. Reassuringly the bone loss induced by AI therapy appears to partially recover after completion of treatment^{22,23}.

Management of cancer treatment induced bone loss

Management of the bone loss associated with cancer therapies includes both lifestyle recommendations and pharmacological intervention²⁴⁻²⁶. All patients at risk of bone loss should be advised to take regular weight bearing exercise²⁷⁻²⁹ and reduce smoking and alcohol consumption³.

Pharmacological intervention for patients at risk of bone loss includes vitamin D supplementation (1000-2000 IU daily) as many breast cancer patients are not replete with vitamin D³⁰. In addition, calcium supplementation (1000mg daily) is recommended if dietary intake is inadequate. Anti-resorptive therapies have been proven to be effective in preventing CTIBL, although their efficacy is influenced by menopausal status and the rate of bone loss^{1,24-26}.

Current fracture risk assessment tools are based on data from healthy postmenopausal women and do not adequately address the risks associated with treatments in younger premenopausal women. Guidelines from an UK expert panel²⁴ for premenopausal women with breast cancer have been published and discussed in a recent review by Hadji *et al*²⁶. Recommendations included informing patients of the risk of bone loss during cancer therapy and consideration of the use of bisphosphonates if the T score is <-2.0. However, how changes in BMD correlate to fracture risk needs further assessment since previous studies in premenopausal women have used either changes in BMD or biochemical markers of bone resorption as surrogates for fracture risk²⁹.

The evaluation of BMD and use of the WHO Fracture Risk Assessment Tool (FRAX) in postmenopausal women provides a reliable estimate of fracture risk. However FRAX does not include anti-cancer treatments as a specific risk factor, and so may underestimate risk^{3,31}. Published guidelines recommend evaluation of BMD, fracture risk assessment and measurement of serum calcium, parathyroid hormone and 25-OH-vitamin D levels before and during AI therapy^{24,26,32}. Antiresorptive therapy is recommended in patients with a baseline T score of <-2.0 or two or more clinical risk factors for fracture^{1,24,25}.

In *premenopausal* women zoledronic acid, the most potent available bisphosphonate, has been shown at a dose of 4mg every 6 months to prevent the significant bone loss associated with goserelin + tamoxifen/anastrozole¹⁴. This schedule of zoledronic acid has also been shown to prevent bone loss associated with ovarian failure due to chemotherapy^{9,33,34}. Other bisphosphonates have shown some ability to prevent the marked bone loss associated with ovarian suppression/failure but do not have a sustained effect on BMD in this population^{10,11,35}.

Zoledronic acid in addition to calcium and vitamin D supplementation is therefore recommended to combat the rapid bone loss in this clinical setting^{1,26}.

In *postmenopausal* women the choice of bisphosphonate is broader with evidence that ibandronate (150mg oral monthly)³⁶, clodronate (1600mg oral daily)⁸, risedronate (35mg oral weekly)³⁷, alendronate (70mg oral weekly)³⁸ and zoledronic acid (4mg IV 6 monthly)³⁹⁻⁴¹ all prevent the bone loss associated with use of AIs. Although these trials were not designed for a fracture-prevention end point, data from the osteoporosis setting have demonstrated a good correlation between BMD improvements and fracture prevention¹. Recently the more potent osteoclast inhibitor, denosumab, has been shown to halve the incidence and significantly extend the time to first clinical fracture in postmenopausal women receiving AIs, irrespective of baseline BMD⁴².

Toxicity and adherence

Although oral bisphosphonates are generally well tolerated, treatment adherence is reported to be poor, with up to 70% of patients discontinuing treatment in the first year⁴³. Intravenous bisphosphonates avoid this issue but are associated with acute phase reactions and renal dysfunction⁴⁴ requiring renal monitoring and dose reductions for renal impairment.

Osteonecrosis of the jaw (ONJ) is the most important adverse event associated with prolonged administration of potent inhibitors of bone resorption. ONJ is more common (incidence ~1.3%)⁴⁵ when intravenous bisphosphonates are used monthly in the setting of advanced cancer but rare with less intensive use of intravenous bisphosphonates (6 monthly) or with oral bisphosphonates given for preservation of bone mass⁴⁶. Nevertheless, before bisphosphonates are initiated it is recommended that patients undergo a dental examination and maintain good

oral hygiene whilst on treatment, avoiding invasive dental surgical procedures such as extractions or implant placement¹.

Panel recommendations:

The panel agreed that treatment decisions should take into account risk factors for fracture and measurement of BMD in all women receiving adjuvant therapy. Premenopausal women receiving OFS, especially when combined with an aromatase inhibitor, were considered the highest priority for treatment and pharmacological intervention was least relevant for premenopausal women on tamoxifen alone. The panel recommended that treatment is continued until the adjuvant breast cancer treatment programme is complete, taking note of BMD results, but not continued indefinitely. Other than a preference for zoledronic acid in premenopausal women, there was variable preference on the choice of agent in postmenopausal women. Although there is not a specific license for bisphosphonate use in early breast cancer, the panel did not consider this a barrier to prescribing these agents (Table 1).

Adjuvant use of bisphosphonates for prevention of metastases

Pre-clinical and early phase clinical trial data

Pre-clinical studies using *in vivo* model systems have evaluated the anti-cancer properties of bisphosphonates at various stages of breast cancer progression (Figure 3) and demonstrated an ability to:

- 1) *prevent homing of tumour cells to bone* using zoledronic acid⁴⁷, ibandronate⁴⁸ and olpadronate⁴⁹ administered before tumour cell injection. In support of this, clinical

- studies have shown that both zoledronic acid⁵⁰⁻⁵² and ibandronate⁵³ decrease the number of DTCs in bone marrow aspirates from breast cancer patients;
- 2) *cause direct induction of tumour cell death in bone* when combined with chemotherapy *in vivo*⁵⁴;
 - 3) *maintain dormancy of tumour cells in bone* with *in vivo* studies demonstrating that zoledronic acid⁵⁰ can prevent proliferation of dormant tumour cells in bone following increased bone turnover secondary to ovariectomy⁵⁵;
 - 4) *inhibit release of growth factors from bone and interruption of the vicious cycle of bone metastasis* with *in vivo* data showing that bisphosphonates can slow tumour progression once bone metastases are formed⁵⁶⁻⁵⁹, if used on a repeated schedule and especially in combination with chemotherapy⁶⁰.

These pre-clinical data showing an anti-tumour effect of bisphosphonates provided scientific rational for the subsequent randomised controlled clinical trials.

Adjuvant clinical trials of bisphosphonates to prevent metastases

Three randomised breast cancer trials initiated in the 1990s assessed the use of the oral bisphosphonate clodronate in addition to standard adjuvant therapy. The results were inconsistent with two trials reporting a reduction in bone recurrence and improved overall survival^{61,62}, while the third suggested an adverse effect of clodronate with an increase in extraosseous metastases⁶³ (figure 1). Subsequent adjuvant trials were performed that recruited larger numbers of patients to receive oral bisphosphonates (NSABP-B34 with clodronate⁶⁴; German GAIN study with ibandronate⁶⁵ and the Danish collaborative trial with pamidronate⁶⁶) or the more potent intravenous bisphosphonate zoledronic acid (AZURE⁶⁷ and ABCSG-12⁶⁸; figure 2). It was the results of these subsequent clinical trials that first identified a probable link

between improved disease free survival (DFS) outcomes with zoledronic acid in patients with low levels of female hormones at initiation of adjuvant therapy (discussed below). In addition, preclinical data supported the hypothesis that adjuvant bisphosphonates can prevent metastases and improve disease outcomes in the presence of low levels of both female and male hormones. An *in vivo* study evaluated the effects of zoledronic acid on the growth of DTCs in bone comparing ovariectomised (OVX) mice (modeling postmenopausal disease) and sham-operated mice (modeling premenopausal disease). The number of detectable tumours in bone was only reduced by zoledronic acid treatment in OVX animals, with no effect in sham-operated animals⁵⁵. These data have been further supported by the same group using a prostate cancer model, with the ability of DTCs in bone to form detectable tumours inhibited by zoledronic acid only in castrated mice, not sham-operated⁵⁶. The molecular mechanisms driving this differential effect of the drugs according to prevailing hormone levels remains an active area of research.

Adjuvant clinical trials of bisphosphonates demonstrating the influence of menopausal status on DFS outcomes.

The ABCSG-12 trial results were thought provoking. Although primarily a trial to evaluate different endocrine strategies including ovarian suppression with goserelin plus either tamoxifen or letrozole for good prognosis ER+ve premenopausal breast cancer, the 2 x 2 randomisation including 6 monthly zoledronic acid or control enabled evaluation of this bisphosphonate on disease outcomes. After 94.4 months median follow-up, relative risks of disease progression (HR=0.77; 95%CI, 0.60-0.99; $P=.042$) and of death (HR=0.66; 95%CI, 0.43-1.02; $P=.064$) remain reduced by zoledronic acid⁶⁹.

Shortly after publication of the initial findings from ABCSG-12⁶⁸, the first results from the AZURE trial were announced. In this larger study, including both pre and postmenopausal women with

ER+ or ER- breast cancers, no improvements in either DFS or overall survival (OS) were seen⁷⁰. However, women with established menopause at study entry (>5 years since last menses) did appear to benefit, leading to the hypothesis that the benefits of adjuvant bisphosphonates are (largely) restricted to women with low levels of reproductive hormones, achieved either through natural menopause or ovarian suppression therapy. The NSABP-B34⁶⁴ and GAIN trials⁶⁵ also failed to demonstrate a significant benefit with bisphosphonates in the overall population. However, both studies suggested benefits of bisphosphonates in older patients (NSABP-B-34 over the age of 50; GAIN over the age of 60) providing further support to the hypothesis.

Several other trials evaluating zoledronic acid primarily as a bone protector during aromatase inhibitor treatment for postmenopausal breast cancer also investigated the effects of bisphosphonate use on disease outcomes^{40,71,72}. The largest of these (ZO-FAST)⁷¹ reported fewer recurrences in women receiving immediate bone protection with zoledronic acid compared with the control arm where the bisphosphonate was only introduced months or years later if there were changes in BMD or a fracture that warranted intervention.

The improvement in disease outcomes in both the zoledronic acid and oral clodronate trials were predominantly and most consistently mediated by a reduction in bone metastases as the first distant metastatic site. The AZURE trial also reported different effects of zoledronic acid on extra-skeletal recurrence by menopausal status with benefit in postmenopausal women and an adverse impact on relapse outside bone in women who were premenopausal at study entry⁶⁷. However, this heterogeneity of response outside bone has not been observed in other trials.

Meta-analysis of adjuvant bisphosphonate trial data

Several selective, study level meta-analyses have been published suggesting a benefit in disease outcomes across adjuvant bisphosphonate trials with a variety of agents⁴¹. One of these specifically estimated the benefit in postmenopausal women and reported a significant improvement in DFS (HR=0.82; 95% CI: 0.74-0.92, $P<0.001$)⁷³. These data supported the notion that adjuvant bisphosphonates are likely to be most effective when there are low levels of female reproductive hormones due to natural/chemical menopause and helped trigger a more detailed meta-analysis.

To investigate the available evidence in a more robust and precise fashion, the Early Breast Cancer Trials Collaborative Group (EBCTCG) has conducted a formal individual patient data meta-analysis of data from 18,766 women involved in 26 randomised trials of adjuvant bisphosphonates for early breast cancer⁷⁴. The majority of these patients received either oral clodronate 1600mg daily or intravenous zoledronic acid 4mg every 6 months or more frequent dosing as per the AZURE schedule⁶⁷. 3,453 and 2,106 breast cancer recurrences and deaths were reported respectively. For the entire population, bisphosphonates did reduce the number of patients with first distant recurrence in bone (RR=0.83; 95%CI 0.73-0.94, $2p=0.004$), but had less clear effects on time to any breast cancer recurrence (RR=0.94; 95%CI 0.87-1.01, $2p=0.08$), distant recurrence (RR=0.92; 95%CI 0.85-0.99, $2p=0.03$) or breast cancer mortality (RR=0.91; 95%CI 0.83-0.99, $2p=0.04$). However, in postmenopausal women (n=11767), bisphosphonates not only improved recurrence in bone (RR=0.72; 95%CI 0.60-0.86, $2p=0.002$) but also overall breast cancer recurrence (RR=0.86; 95%CI 0.78-0.94, $2p=0.002$), distant recurrence at any site (RR=0.82; 95%CI 0.73-0.92, $2p=0.003$) and breast cancer mortality (RR=0.82; 95%CI 0.73-0.93, $2p=0.002$). Bisphosphonates did not appear to modify any disease outcomes in premenopausal

women with a borderline significance test for heterogeneity by menopausal status ($2p=.06$). These results were maintained in a sensitivity analysis where the hypothesis generating trials (ABCSG-12 and AZURE) were omitted; without these trials postmenopausal women continuing to show benefit across key recurrence and survival endpoints.

The risk reductions for relapse and mortality in postmenopausal women treated with bisphosphonates were similar irrespective of ER status or grade of the primary tumour, axillary lymph node involvement and use/non use of chemotherapy, suggesting that menopausal status should be the main criterion for selection of patients for adjuvant bisphosphonates to prevent metastases.

The data also suggest that menopausal status at the initiation of adjuvant bisphosphonates is important. If this were not so, benefit would also be expected in women rendered postmenopausal by adjuvant chemotherapy. However, with the exception of women receiving ovarian suppression therapy at the start of adjuvant bisphosphonates, neither the AZURE data nor the meta-analysis could identify a subset of premenopausal women, for example those aged >45 years who have a very high likelihood of developing a chemotherapy induced menopause, who derived benefit from adjuvant bisphosphonates. This indicates the initial interaction between bisphosphonates and endocrine/paracrine factors in the bone microenvironment differentially influences the survival of tumour cells already disseminated into the bone/ bone marrow microenvironment at diagnosis (reviewed in Wilson et al ⁷⁵).

Patient selection, choice of agent, dose and duration of therapy

A clinical definition of 'postmenopausal' status, based on the widely accepted WHO definition (*the permanent cessation of menstruation determined retrospectively after 12 months of amenorrhoea without any other pathological or physiological cause*)⁷⁶, could be utilised in selecting patients for adjuvant bisphosphonates (see Figure 4). Biochemical classification of menopausal status based on serum FSH levels in the postmenopausal range prior to initiation of treatment may be of use in patients whose clinical status is unknown e.g. due to hysterectomy or intrauterine devices. For those women who are not postmenopausal, bisphosphonates could be considered if treatment with GnRH/LHRH analogues is planned as part of adjuvant therapy, and continued for the duration of the ovarian suppression.

The meta-analysis was unable to demonstrate any important difference in disease outcome by type of bisphosphonate (amino vs non-amino), with the outcomes in the clodronate trials at least as good as those achieved with the more potent aminobisphosphonates. Additional data in support of this comes from the recently reported SWOG trial that showed no difference in DFS outcomes following 3 years of adjuvant clodronate, ibandronate and zoledronic acid⁷⁷. The meta-analysis also found the intense treatment schedules of zoledronic acid, as used in AZURE, were of similar efficacy to the less intensive schedules of zoledronic acid 6 monthly or daily oral clodronate or ibandronate. There are no direct comparisons of duration of bisphosphonate treatment although the SUCCESS trial (NCT02181101) comparing 3 years or 5 years zoledronic acid will help address this. In the meta-analysis, treatment benefits appeared early but there were insufficient data from trials of short-term (<2 years) adjuvant bisphosphonate use to recommend short durations of therapy with most of the data supporting treatment for 3-5 years.

Neither alendronate or risedronate have been adequately evaluated in randomised adjuvant clinical trials. A retrospective review of over 20,000 women treated with osteoporosis doses of oral alendronate, risedronate or etidronate, either following a breast cancer diagnosis or started prior to and continued after diagnosis suggested that exposure to these agents reduced the risk of relapse and improved survival⁷⁸. However, despite their established role in the prevention of osteoporosis, there are insufficient data to recommend their use for metastasis prevention.

Panel recommendations

There was strong consensus that the data supported the use of adjuvant bisphosphonates in postmenopausal (whether natural or induced) women, with some experts (58%) suggesting further restriction to those considered at intermediate or high risk of recurrence rather than unselected use across all risk groups. There was consensus that a lack of regulatory approval for bisphosphonates in this setting should not preclude their use, with the majority indicating they could administer adjuvant bisphosphonates in their health care system as an off label treatment based on a locally or nationally defined protocol or treatment guideline. The Panel was in agreement that either daily oral clodronate or intravenous zoledronic acid (Q6 monthly) are the preferred agents for metastasis prevention and recommended that the potential risks and benefits of adjuvant bone targeted treatment for 3-5 years alongside vitamin D supplementation and adequate calcium intake should be discussed with relevant patients (table 2). With these regimens the risk of ONJ is <1%.

Summary of treatment recommendations

The overall consensus was that bisphosphonates should be used as part of routine clinical practice in the adjuvant management of CTIBL in 'at risk' patients and in the prevention of

metastases in patients with low levels of female sex hormones (see figure 5). Ongoing adjuvant trials of the osteoclast inhibitor denosumab (D-CARE) will provide further information on the clinical role of mechanistically different adjuvant bone targeted treatments.

Acknowledgements

We thank Dr Janet Horseman at the Cancer Clinical Trials Unit, Weston Park Hospital, Sheffield, UK for her assistance with data management.

Funding

The consensus meeting received financial support from the BANSS Foundation, a nonprofit body based in Biedenkopf an der Lahn, Germany. No pharmaceutical support was received for this work.

Disclosures

Prof RE Coleman has provided expert testimony on behalf of Novartis concerning litigation in cases of osteonecrosis of the jaw and received research grants from Amgen, Bayer and Celgene.

Prof M Aapro has been a consultant for and received honoraria for lectures at symposia for Abraxis, Amgen, Astellas, Bayer Schering, BMS, CArisLifeScience, Celgene, Cephalon, Eisai, Ferring, GENomicHealth, GSK, Helsinn, Hospira, Ipsen, Orthobiotech, Novartis, Merck, Merck Serono, Pfizer, Piere Fabre, Roche, Sandoz, Teva, Vifor.

Prof Hadji has given lectures for Novartis and Amgen. Prof Costa has received speaker fees and research grants from Amgen and Novartis. Dr Wilson has received speaker fees from Amgen.

Prof Thurlimann owns stock in Novartis and Amgen and has received honoraria from Roche.

Prof Cortes has received consultancy fees from Roche, Celgene and speaker fees from Roche, Celgene, Novartis and Eisai. Prof Markopoulos has received research grants from AstraZeneca (AZ). Prof Di Leo has received consultant fees from Roche, AZ, Pfizer and Novartis and conducted research funded by AZ and Pfizer. Prof Gnant has received research grants from Sanofi-Aventis, Novartis, Roche, GlaxoSmithKline, Pfizer, Smith Medical and consultancy from AZ, Novartis and Acceisiors and speaker fees from Amgen, Novartis, GlaxoSmithKline, AZ, Roche.

Prof Cameron has received research grants from Amgen, Novartis and Roche. Prof Martin has received speaker fees and research funding from Novartis. Prof Ejlertsen has received research funding from Novartis, Amgen, Roche and Nanostring. All remaining authors have declared no conflicts of interest.

References

1. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelinesdagger. *Ann Oncol* 2014;25 Suppl 3:iii124-iii37.
2. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. *Am J Public Health* 1984;74:979-83.
3. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. *Osteoporos Int* 2007;18:1033-46.
4. Eastell R, Hannon R. Long-term effects of aromatase inhibitors on bone. *J Steroid Biochem Mol Biol* 2005;95:151-4.
5. Nicks KM, Fowler TW, Akel NS, Perrien DS, Suva LJ, Gaddy D. Bone turnover across the menopause transition : The role of gonadal inhibins. *Ann N Y Acad Sci* 2010;1192:153-60.
6. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. *Eur J Cancer* 2001;37:2373-8.
7. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. *Nat Rev Rheumatol* 2013;9:365-74.
8. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. *J Clin Oncol* 1997;15:1341-7.

9. Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. *Eur J Cancer* 2011;47:683-9.
10. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. *J Natl Cancer Inst* 1998;90:704-8.
11. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. *J Clin Oncol* 1997;15:955-62.
12. Sverrisdottir A FT, Jacobsson H. Bone Mineral Density Among Premenopausal Women With Early Breast Cancer in a Randomized Trial of Adjuvant Endocrine Therapy. *Journal of Clincial Oncology* 2004;22:3694-9.
13. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). *Osteoporos Int* 2003;14:1001-6.
14. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. *Lancet Oncol* 2008;9:840-9.
15. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2015;372:436-46.
16. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. *J Clin Oncol* 1996;14:78-84.

17. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. *J Clin Oncol* 2014;32:2255-69.
18. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 2005;97:1652-62.
19. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. *Breast Cancer Res* 2007;9:R52.
20. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *N Engl J Med* 2009;361:766-76.
21. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet* 2014;383:1041-8.
22. Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. *Ann Oncol* 2011;22:857-62.
23. Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. *Breast Cancer Res Treat* 2010;124:153-61.
24. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. *Cancer Treat Rev* 2008;34 Suppl 1:S3-18.
25. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. *Ann Oncol* 2011;22:2546-55.

26. Hadji P, Gnani M, Body JJ, et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? *Cancer Treat Rev* 2012;38:798-806.
27. Peppone LJ, Mustian KM, Janelsins MC, et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. *Clin Breast Cancer* 2010;10:224-9.
28. Winters-Stone KM, Dobek J, Nail L, et al. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. *Breast Cancer Res Treat* 2011;127:447-56.
29. Waltman NL, Twiss JJ, Ott CD, et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. *Osteoporos Int* 2010;21:1361-9.
30. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. *Eur J Cancer* 2010;46:2196-205.
31. Silverman SL, Calderon AD. The utility and limitations of FRAX: A US perspective. *Curr Osteoporos Rep* 2010;8:192-7.
32. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 2003;21:4042-57.
33. Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. *J Clin Oncol* 2008;26:4739-45.
34. Kim JE, Ahn JH, Jung KH, et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). *Breast Cancer Res Treat* 2011;125:99-106.

35. Hines SL, Mincey BA, Sloan JA, et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. *J Clin Oncol* 2009;27:1047-53.
36. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. *Clin Cancer Res* 2008;14:6336-42.
37. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. *J Clin Oncol* 2010;28:967-75.
38. Yamada K KN, Endoh K et al. The role of bisphosphonates and bone health issues in Japanese breast cancer patients: efficacy of alendronate with aromatase inhibitors. *J Clin Oncol* 2006;24(suppl):Abst 10777.
39. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. *J Clin Oncol* 2007;25:829-36.
40. Llombart A, Frassoldati A, Paija O, et al. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. *Clin Breast Cancer* 2012;12:40-8.
41. Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. *Oncologist* 2013;18:353-61.
42. Gnani M, Pfeiler G, Dubsy PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2015;386:433-43.
43. Hadji P, Claus V, Ziller V, Intorcchia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. *Osteoporos Int* 2012;23:223-31.

44. Wilson C, Coleman RE. Adjuvant therapy with bone-targeted agents. *Curr Opin Support Palliat Care* 2011;5:241-50.
45. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Ann Oncol* 2012;23:1341-7.
46. Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. *Nat Rev Endocrinol* 2011;7:34-42.
47. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. *J Natl Cancer Inst* 2007;99:322-30.
48. Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. *International journal of cancer Journal international du cancer* 2003;107:468-77.
49. van der Pluijm G, Que I, Sijmons B, et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. *Cancer research* 2005;65:7682-90.
50. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. *The lancet oncology* 2010;11:421-8.
51. Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. *Anticancer Res* 2010;30:1807-13.

52. Banys M, Solomayer EF, Gebauer G, et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. *BMC cancer* 2013;13:480.
53. Hoffmann O, Aktas B, Goldnau C, et al. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. *Anticancer Res* 2011;31:3623-8.
54. Brown HK OP, Evans CE, Coleman RE, Holen I. A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. *Journal of Bone Oncology* 2012;1:47-56.
55. Ottewell PD, Wang N, Brown HK, et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. *Clin Cancer Res* 2014;20:2922-32.
56. Ottewell PD, Wang N, Meek J, et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. *Endocrine-related cancer* 2014;21:769-81.
57. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. *Clin Cancer Res* 2006;12:6222s-30s.
58. Zheng Y, Zhou H, Brennan K, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. *Bone* 2007;40:471-8.
59. Buijs JT, Que I, Lowik CW, Papapoulos SE, van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. *Bone* 2009;44:380-6.
60. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. *Breast Cancer Res* 2010;12:214.

61. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. *Ann Oncol* 2008;19:2007-11.
62. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. *Breast Cancer Res* 2006;8:R13.
63. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. *Acta Oncol* 2004;43:650-6.
64. Paterson AH, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. *The lancet oncology* 2012;13:734-42.
65. von Minckwitz G, Mobus V, Schneeweiss A, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. *J Clin Oncol* 2013;31:3531-9.
66. Kristensen B, Ejlersen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. *Acta Oncol* 2008;47:740-6.
67. Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. *Lancet Oncol* 2014;15:997-1006.
68. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. *N Engl J Med* 2009;360:679-91.

69. Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. *Ann Oncol* 2015;26:313-20.
70. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. *N Engl J Med* 2011;365:1396-405.
71. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. *Cancer* 2008;112:1001-10.
72. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. *Ann Oncol* 2013;24:398-405.
73. Gregory W MH, Coleman RE et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. *J Clin Oncol* 2012;30:supp; abst 513.
74. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet* 2015.
75. Wilson C, Holen I, Coleman RE. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. *Cancer Treat Rev* 2012;38:877-89.
76. WHO. WHO technical report series; 866. In: Organization WH, ed. WHO Scientific Group on Research on the Menopause in the 1990s. Geneva; 1996.

77. Gralow J BW, Paterson AHG, Lew D et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. In: 2015 ASCO Annual Meeting; 2015: J Clin Oncol; 2015.
78. Kremer R, Gagnon B, Meguerditchian AN, Nadeau L, Mayo N. Effect of Oral Bisphosphonates for Osteoporosis on Development of Skeletal Metastases in Women With Breast Cancer: Results From a Pharmaco-epidemiological Study. J Natl Cancer Inst 2014;106.
79. Haider MT, Holen I, Dear TN, Hunter K, Brown HK. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone 2014; 66: 240-250.
80. Coscia M, Quaglino E, Lezzi M, Curcio C et al. Zoledronic acid repolarises tumour associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14:2803-15
81. Benzaid I, Monkkonen H, Stresing V, Clezardin P et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011;71:4562-72

Figure and table legends

Figure 1: Summary of major adjuvant trials evaluating oral bisphosphonates in early breast cancer

Figure 2: Summary of major adjuvant trials evaluating intravenous zoledronic acid in early breast cancer.

Figure 3: Potential effects of BPs in bone metastases

Figure 4: Selection of patients suitable for adjuvant bisphosphonates to prevent metastases


Figure 5: Summary of key clinical points and levels of evidence for adjuvant BP treatment recommendations

Table 1: Adjuvant bisphosphonate use to prevent osteoporosis and fracture

Table 2: Adjuvant bisphosphonates to prevent metastases in early breast cancer


Trial population [ref]	Trial design	Outcomes
Diel et al [61] n= 302 Stage I=III Premenopausal 36% Postmenopausal 64% ER+ve 75% ER-ve 25% DTC+ve bone marrow	Oral clodronate 1600mg daily vs placebo for 2 years	Significant reduction in the incidence of bone metastases ($p=0.003$) and improved survival ($p=0.001$) for clodronate.
Powles et al [62] n= 1069 Stage I-III Premenopausal 50% Postmenopausal 50% ER+ve 64% ER-ve 36%	Oral clodronate 1600mg daily vs placebo for 2 years	Significantly reduced incidence of bone metastases (HR 0.692 $p=0.043$) and improved OS (HR 0.768 $p=0.048$) for clodronate. Nb. in a sub group analysis, postmenopausal women had the greatest disease outcome benefit from clodronate
Saarto et al [63] n=299 Stage II-III Premenopausal 48% Postmenopausal 52% ER+ve 61% ER-ve 39%	Oral clodronate 1600mg daily vs placebo for 3 years	Increase in extraosseous metastases (45% vs 32%) in clodronate group with increased risk of death (46% vs 38%). In a sub group analysis postmenopausal women with ER+ve disease did not gain a negative effect from clodronate.
Paterson et al [64] (NSABP-B-34) n= 3323 Stage I-III Premenopausal % Postmenopausal % ER+ve 78 % ER-ve 22%	Oral clodronate 1600mg daily vs placebo for 3 years	No significant difference in DFS between groups. Post hoc analysis in women >60 years shown a significantly improved bone (HR 0.64 95%CI 0.4-0.95 $p=0.047$) and extraosseous (HR 0.63 95%CI 0.43-0.91 $p=0.014$) metastasis free survival for clodronate.
Von Minckwitz et al (German GAIN study) [65] n= 2015 Stage II-III Premenopausal 48% Postmenopausal 52% ER+ve 76% ER-ve 23%	Oral ibandronate 50mg daily vs placebo for 2 years	No significant difference in DFS (HR 0.945 95% CI 0.768 -1.161 $p=0.589$) or OS (HR1.04 95%CI 0.763-1.419 $p=0.803$) between groups. DFS was non significantly longer in women <40 and >60 years.
Kristensen et al [66] n= 953 Stage I-II Premenopausal 67 % Postmenopausal 33 % ER+ve ~15 % ER-ve~60 %	Oral pamidronate 150mg twice daily vs placebo for 4 years	No significant difference in DFS (HR 1.03 95%CI 0.75-1.4 $p=0.86$) or OS between groups.

Trial population [ref]	Trial design	Outcomes
<p>AZURE [70] n=3360 Stage II/III Premenopausal 45% Unknown menopausal 9.7% <5 years since menopause 14.7% >5 years since menopause 31% ER+ve 78.9% ER-ve 21%</p>	<div style="border: 1px solid black; padding: 5px; text-align: center;">Standard therapy (ST)</div> <p style="text-align: center;">VS</p> <div style="border: 1px solid black; padding: 5px; text-align: center;">Standard therapy +ZOL 4mg 6 doses Q3-4/52, 8 doses Q3/12, 5 doses Q6/12</div> <p style="text-align: center;">ZOL duration 5 years</p>	<p>No significant difference between groups for DFS or OS. In women >5 years postmenopausal the zoledronic acid group had a 25% relative risk reduction for invasive DFS (HR 0.75 95%CI 0.59-0.96 p=0.02) and risk of death by 26% (HR 0.74 95%CI 0.55-0.98 p=0.04)</p>
<p>ABCSG-12 [68] n=1803 Stage I/II Premenopausal All ER+ve</p>	<div style="border: 1px solid black; padding: 5px; text-align: center;">Goserelin 3.6mg + tamoxifen 20mg</div> <p style="text-align: center;">VS</p> <div style="border: 1px solid black; padding: 5px; text-align: center;">Goserelin +anastrozole 1mg</div> <p style="text-align: center;">VS</p> <div style="border: 1px solid black; padding: 5px; text-align: center;">Goserelin+tamoxifen +ZOL 4mg Q6/12</div> <p style="text-align: center;">VS</p> <div style="border: 1px solid black; padding: 5px; text-align: center;">Goserelin+anastrozole+ZOL 4mg Q6/12</div> <p style="text-align: center;">ZOL duration 3 years</p>	<p>Relative risk reduction of 29% for DFS with zoledronic acid compared to endocrine therapy alone (HR 0.71 95%CI 0.55-0.92). OS did not alter with addition of zoledronic acid in overall population. A significant benefit for OS was seen in women >40 years (HR 0.57 95%CI 0.33-0.99 p=0.042).</p>
<p>Zo-FAST [72] n=1060 Stage I-III All Postmenopausal All ER+ve</p>	<div style="border: 1px solid black; padding: 5px; text-align: center;">Letrozole 2.5mg +ZOL 4mg Q6/12</div> <p style="text-align: center;">VS</p> <div style="border: 1px solid black; padding: 5px; text-align: center;">Letrozole + delayed ZOL (started if; BMD T score <-2SD, Clinical fracture, asymptomatic fracture at 36/12)</div> <p style="text-align: center;">ZOL duration 5 years</p>	<p>Patients who started zoledronic acid immediately had a 34% relative risk decrease for DFS (HR 0.66 95%CI 0.44-0.97 p=0.0375). There was no difference in OS. Women >60 years or >5 years postmenopausal had a significantly improved OS with immediate zoledronic acid (HR 0.5 p=0.0224)</p>



Other cell types in the bone/tumour microenvironment shown to be affected by BPs:

- **Osteoblasts:** Reduced by a single dose of Zol *in vivo* (79)
- **Macrophages:** Increased polarisation to M1 anti-tumour phenotype in mammary tumour, no evidence from bone metastasis models (80)
- **Immune cells:** Stimulation of immune cells by BPs affects tumour growth specifically in those tumours outside bone (81)



Summary of key clinical points and levels of evidence for adjuvant BP treatment recommendations

Prevention of CTIBL

Premenopausal women not receiving adjuvant ovarian suppression

- Chemotherapy unlikely to have a direct affect on bone
- Tamoxifen induces bone loss – long term effects need to be established
- Assessment of fracture risk should include BMD assessment
- Consider BPs if T score ≤ 2.0

Postmenopausal women at low risk of recurrence

- Chemotherapy unlikely to have a direct affect on bone
- Tamoxifen reduces fracture risk
- AIs induce bone loss
- Assessment of fracture risk should include FRAX assessment and BMD assessment
- Ensure adequate calcium and vitamin D intake
- Consider BPs if T score ≤ 2.0 or ≥ 2 clinic risk factors for fracture
- BPs can include alendronate (70mg PO weekly), risedronate (35mg PO weekly), ibandronate (150mg PO monthly), zoledronic acid (4mg IV Q6 months), clodronate (1600mg PO daily) (I,A)

Prevention of metastases and improving disease outcomes

Premenopausal women on adjuvant ovarian suppression

- BPs should be considered to prevent CTIBL and metastases (I,A)
- Recommended BP is zoledronic acid (4mg IV Q6 months) or clodronate (1600mg PO daily) (I,A)
- BPs should be initiated at the start of adjuvant therapy (II,A)
- Duration of BP treatment should not exceed duration of ovarian suppression unless indicated for low T score (3-5 years) (II,A)

Postmenopausal women at intermediate or high risk of recurrence

- BPs should be considered to prevent metastases irrespective of fracture risk (1,A)
- Recommended BPs are zoledronic acid (4mg IV Q6 months) or clodronate (1600mg PO daily) (1,A) alongside vitamin D supplementation and adequate calcium intake
- BPs should be initiated at the start of adjuvant therapy (II,A)
- Duration of BP treatment should be 3-5 years and only continued after 5 years if indicated by fracture risk (II,A)

Table 1

Areas of strong consensus (>80%)

- Should be considered in premenopausal women on ovarian suppression and an aromatase inhibitor
Agree 23 (16+7; 96%); Disagree 1 (0+1; 4%); Neutral/abstain 0 (0%);
- When used bisphosphonates should not be continued indefinitely
Agree 20 (11+9; 83%); Disagree 0 (0%); Neutral/abstain 4 (17%);

Areas of modest consensus (60-80%)*

- Treatment should be based on fracture risk algorithms +/- BMD results
Agree 17 (8+9; 71%); Disagree 3 (2+1; 12%); Neutral/abstain 4 (17%);
- Should be considered in premenopausal women on ovarian suppression and tamoxifen
Agree 17 (9+8; 71%); Disagree 4 (0+4; 17%); Neutral/abstain 3 (12%);
- Zoledronic acid is the preferred agent for women receiving ovarian suppression
Agree 17 (6+11; 71%); Disagree 5 (1+1; 21%); Neutral/abstain 2 (8%);
- When used, bisphosphonates should be continued until the adjuvant treatment programme is complete
Agree 17 (6+11; 71%); Disagree 4 (1+3; 17%); Neutral/abstain 3 (13%);
- Bisphosphonates can be given in my health care system for this indication
Agree 17 (6+11; 71%); Disagree 3 (0+3; 12%); Neutral/abstain 4 (17%);
- Duration should depend on BMD results
Agree 14 (4+10; 58%); Disagree 5 (1+4; 21%); Neutral/abstain 5 (21%);
- Is not required in premenopausal women on tamoxifen alone
Agree 15 (5+10; 62%); Disagree 4 (2+2; 17%); Neutral/abstain 5 (21%);

Areas of uncertainty or lack of consensus

- Treatment decisions should not be based on BMD results alone
Agree 12 (3+9; 50%); Disagree 9 (1+8; 37%); Neutral/abstain 3 (12%);
- Does not need to be considered in postmenopausal women on tamoxifen alone
Agree 11 (1+10; 46%); Disagree 8 (3+5; 33%); Neutral/abstain 5 (21%);
- Should be restricted to postmenopausal women receiving an AI
Agree 12 (0+12; 50%); Disagree 9 (7+2; 37%); Neutral/abstain 3 (12%);
- Any bisphosphonate can be used for postmenopausal women
Agree 13 (3+10; 54%); Disagree 9 (3+6; 37%); Neutral/abstain 2 (8%);
- Any bisphosphonate can be used for premenopausal women
Agree 9 (0+9; 37%); Disagree 9 (4+5; 37%); Neutral/abstain 6 (24%);

*Number agreeing (strongly + slightly; %); number disagreeing (strongly + slightly; %)

Table 2

Areas of strong consensus (>80%)

- Should be considered because the data are conclusive
Agree 20 (17+3; 83%); Disagree 2 (1+1; 8%); Neutral/abstain 2 (8%);
- Should be considered in postmenopausal women
Agree 22 (14+8; 92%); Disagree 1 (0+1; 4%); Neutral/abstain 1 (4%);
- Should not be considered in premenopausal women
Agree 21 (17+4; 87%); Disagree 1 (0+1; 4%); Neutral/abstain 2 (8%);
- Should be considered in premenopausal women receiving ovarian suppression therapy
Agree 22 (11+11; 92%); Disagree 1 (0+1; 4%); Neutral/abstain 1 (4%);
- Zoledronic acid or oral clodronate are the agents of choice
Agree 21 (16+5; 87%); Disagree 0 (0+0; 0%); Neutral/abstain 3 (12%);

Areas of modest consensus (60-80%)*

- Should not be considered for all women with early breast cancer
Agree 19 (14+5; 79%); Disagree 3 (1+2; 12%); Neutral/abstain 2 (8%);
- Should be considered even though there is no regulatory approval for their use in this setting
Agree 18 (15+3; 75%); Disagree 3 (1+2; 12%); Neutral/abstain 3 (12%);
- When used, 6 monthly zoledronic acid is preferred to more intensive regimens
Agree 17 (12+6; 75%); Disagree 2 (1+1; 8%); Neutral/abstain 4 (17%);
- Can be given in my health care system as an off label treatment based on a locally or nationally defined protocol or treatment guidance
Agree 15 (8+7; 62%); Disagree 6 (3+3; 25%); Neutral/abstain 3 (12%);
- Any bisphosphonate can be used
Agree 3 (1+2; 12%); Disagree 15 (5+10; 62%); Neutral/abstain 6 (25%);
- Should be considered in women with ER-ve early breast cancer
Agree 15 (8+7; 62%); Disagree 5 (2+3; 21%); Neutral/abstain 4 (17%);
- When used, bisphosphonate should be administered for 3-5 years
Agree 15 (8+7; 62%); Disagree 4 (1+3; 17%); Neutral/abstain 5 (21%);

Areas of uncertainty of lack of consensus

- Should only be considered in postmenopausal women considered at intermediate or high risk of recurrence
Agree 14 (7+7; 58%); Disagree 7 (2+5; 29%); Neutral/abstain 3 (12%);
- Should only be considered in postmenopausal women with node positive breast cancer
Agree 7 (5+2; 29%); Disagree 12 (5+5; 50%); Neutral/abstain 5 (21%);
- Weekly oral alendronate or risedronate should not be used
Agree 12 (7+5; 50%); Disagree 4 (0+4; 17%); Neutral/abstain 8 (33%);
- A patient on weekly oral alendronate or risedronate should be changed to zoledronic acid or clodronate
Agree 13 (8+5; 54%); Disagree 5 (0+5; 21%); Neutral/abstain 6 (25%);

*Number agreeing (strongly + slightly; %); number disagreeing (strongly + slightly; %)